[1] JOHNSTON CB, DAGAR M. Osteoporosis in Older Adults. Med Clin North Am. 2020;104(5):873-884.
[2] COTTS KG, CIFU AS. Treatment of Osteoporosis. JAMA. 2018;319(10): 1040-1041.
[3] ENSRUD KE, CRANDALL CJ. Osteoporosis. Ann Intern Med. 2017;167(3): 17-32.
[4] LORENTZON M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med. 2019;285(4):381-394.
[5] LIU Y, YU P, PENG X, et al. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis. J Control Release. 2019;304:39-50.
[6] TANAKA S, MATSUMOTO T. Sclerostin: from bench to bedside. J Bone Miner Metab. 2020 Nov 18. doi: 10.1007/s00774-020-01176-0.
[7] FABRE S, FUNCK-BRENTANO T, COHEN-SOLAL M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. J Clin Med. 2020; 9(11):3439.
[8] 章暐, 邹剑, 张长青. 骨硬化蛋白与绝经后妇女脆性骨折的相关性 [J]. 第二军医大学学报,2017,38(9):1206-1210.
[9] DEAN DB, WATSON JT, JIN W, et al. Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice. J Anat. 2010;216(5):625-630.
[10] HASHIMOTO K, KAITO T, FURUYA M, et al. In vivo dynamic analysis of BMP-2-induced ectopic bone formation. Sci Rep. 2020;10(1):4751.
[11] ZHANG Y, YANG W, DEVIT A, et al. Efficiency of coculture with angiogenic cells or physiological BMP-2 administration on improving osteogenic differentiation and bone formation of MSCs.J Biomed Mater Res A. 2019;107(3):643-653.
[12] SIMPSON AH, MILLS L, NOBLE B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br. 2006;88(6): 701-705.
[13] LIU DB, SUI C, WU TT, et al. Association of Bone Morphogenetic Protein (BMP)/Smad Signaling Pathway with Fracture Healing and Osteogenic Ability in Senile Osteoporotic Fracture in Humans and Rats. Med Sci Monit. 2018;24:4363-4371.
[14] MAJIDINIA M, SADEGHPOUR A, YOUSEFI B. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233(4): 2937-2948.
[15] KAMIYA N, YE L, KOBAYASHI T, et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development. 2008;135(22):3801-3811.
[16] KAMIYA N, KOBAYASHI T, MOCHIDA Y, et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010;25(2):200-210.
[17] KAMIYA N, ATSAWASUWAN P, JOINER DM, et al. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass. Bone. 2020;138:115513.
[18] SEDAGHATI B, JAHROOMISHIRAZI R, STARKE A, et al. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown. Cells Tissues Organs. 2016;201(5):366-379.
[19] 赵明月, 高永红. 老年糖尿病患者饮食对骨质疏松症发生的影响 [J]. 中国现代医药杂志,2020,22(2):47-49.
[20] 洪维, 郑松柏, 李慧林,等. 骨折风险评估工具FRAX?评分判定上海社区老年人群实际骨质疏松性椎体骨折(OVF)效用的研究[J]. 复旦学报(医学版),2020,47(1):83-88+100.
[21] MACÍAS I, ALCORTA-SEVILLANO N, RODRÍGUEZ CI, et al. Osteoporosis and the Potential of Cell-Based Therapeutic Strategies. Int J Mol Sci. 2020;21(5):1653.
[22] ZHANG N, ZHANG ZK, YU Y, et al. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL. Aptamer Therapy. Front Cell Dev Biol. 2020;8:325.
[23] ROCHEFORT GY, PALLU S, BENHAMOU CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010;21(9):1457-1469.
[24] BELLIDO T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014; 94(1):25-34.
[25] CHEN D, ZHAO M, MUNDY GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
[26] TU X, DELGADO-CALLE J, CONDON KW, et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A. 2015;112(5):E478-486.
[27] TRESGUERRES FGF, TORRES J, LÓPEZ-QUILES J, et al. The osteocyte: A multifunctional cell within the bone. Ann Anat. 2020;227:151422.
[28] TSUKASAKI M, TAKAYANAGI H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol. 2019;19(10):626-642.
[29] DIVIETI PAJEVIC P, KRAUSE DS. Osteocyte regulation of bone and blood. Bone. 2019;119:13-18.
[30] SALAZAR VS, GAMER LW, ROSEN V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol. 2016;12(4):203-221.
[31] DUMIC-CULE I, PERIC M, KUCKO L, et al. Bone morphogenetic proteins in fracture repair. Int Orthop. 2018;42(11):2619-2626.
[32] LI P, BAI Y, YIN G, et al. Synergistic and sequential effects of BMP-2, bFGF and VEGF on osteogenic differentiation of rat osteoblasts. J Bone Miner Metab. 2014;32(6):627-635.
[33] HE G, SHI Y, LIM J, et al. Differential involvement of Wnt signaling in Bmp regulation of cancellous versus periosteal bone growth. Bone Res. 2017;5:17016.
[34] MALIK Z, ALEXIOU M, HALLGRIMSSON B, et al. Bone Morphogenetic Protein 2 Coordinates Early Tooth Mineralization. J Dent Res. 2018; 97(7):835-843.
[35] KONG YY, YOSHIDA H, SAROSI I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
[36] UDAGAWA N, KOIDE M, NAKAMURA M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021; 39(1):19-26.
[37] ANDERSEN TL, ABDELGAWAD ME, KRISTENSEN HB, et al. Understanding coupling between bone resorption and formation: are reversal cells the missing link. Am J Pathol. 2013;183(1):235-246.
[38] BOYCE BF, XING L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139-146.
[39] BARON R, KNEISSEL M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2): 179-192.
[40] GLASS DA 2ND, BIALEK P, AHN JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.
[41] KRAMER I, HALLEUX C, KELLER H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30(12):3071-3085.
[42] WEITZMANN MN. Bone and the Immune System. Toxicol Pathol. 2017; 45(7):911-924.
|